We work from Zurich and Warsaw, with an advisory board of senior practitioners.
Fifteen years in pharmaceutical market access and business development, with roles at Roche and Abbott, and earlier communications work at Edelman.
He founded Capital for Cures in 2025 and writes our weekly Insights on royalty and licensing deals.
Partner at Rymarz Zdort Maruta in Warsaw, where he co-heads the Life Sciences practice. Chambers Europe has recommended him as a leading life sciences lawyer in Poland since 2012.
Nearly 20 years in life sciences pricing and market access, including as CEO of Alliance Life Sciences.
Leads InnoSource Ventures, which invests in healthcare and deep-tech companies alongside the multi-family office Toledo Capital.
Led M&A and treasury at MorphoSys (now Novartis), which signed a $2.025bn funding partnership with Royalty Pharma in 2021.
Machine learning PhD from Queen Mary University of London, engineering at Cambridge and postdoctoral research at ETH Zurich.
We are always glad to hear from people interested in royalty financing and life sciences. Write to us at contact@capitalforcures.com.